

*AMT-143: A Phase 1 Randomized
Controlled Trial Evaluating AMT-
143 in Healthy Volunteers to Assess
Sustained Analgesic Release for
Non-Opioid Pain Treatments*

*Dr. Hance Clarke
Dr. Paul Karanicolas*



RFA 3 – Canadian Biotech/RCTs




Accelerating
Clinical Trials
Accélérer les
Essais Cliniques



Canadian Institutes of
Health Research
Instituts de recherche
en santé du Canada


Evaluating Canadian Biotech with RCTs

- AmacaThera Inc.
- AMT-143 (non-opioid anesthetic)
- Post-operative pain




Research Question

- Does AMT-143 provide 3-days of sustained ropivacaine release in humans?



Issue Encountered


- Due to First-In-Human requirements for Healthy volunteer study with PK testing, study was difficult to run in a hospital setting




Design

Subcutaneous administration in healthy volunteers. Dose escalation:

- 100mg
- 200mg
- 400mg



Timeline



Updates

- Significant difficulties were encountered running this Phase 1 trial in a hospital setting
- Identified a site that can run a Phase 2 trial
- Manufactured clinical trial material
- Filed a CTA for Phase 2 study in the hospital setting

